BIIP predicts 40% external sales by 2008

20 February 2006

Chinese drugmaker Broad Intelligence International Pharmaceutical says it expects overseas sales to account for 40% of its turnover in two years time. The firm's forecast is based on its expansion of its over-the-counter drug sales in Japan and other Asian markets.

The firm, which currently derives the majority of its income from the sale of drugs to hospitals and clinics in its home province of Fujian, believes that it could generate 100 million renminbi ($12.4 million) a year in sales from the Japanese OTC market. The firm added that non-Chinese sales would contribute more to its income due in part to the higher drug prices outside the country.

BIIP's chairman, Zhong Houtai, said that the company had seen increased demand for traditional Chinese medicines in Japan, particularly in the drink-related liver disease market, which would be suitable for the firm's anti-hepatitis remedies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight